12:00 AM
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ilaris canakinumab regulatory update

The European Commission approved a label expansion for Ilaris canakinumab from Novartis to include treatment of gouty arthritis. Specifically, Ilaris is approved to treat adults with frequent gouty arthritis attacks - defined as >=3 attacks in the previous 12 months - in whom...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >